Moderna, Inc.

(NASDAQ Global Select)

Moderna (MRNA) stock at a glance

Full Moderna report
Ticker
MRNA
Exchange
NASDAQ Global Select
News sentiment Β· last 30 days
+31 Somewhat Bullish β‰ˆ steady vs. previous 30 days
30-day average of 23 articles Β· scale βˆ’100 to +100

Across 23 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of Moderna news is Somewhat Bullish (+31) on a scale from βˆ’100 to +100. That is about the same as the previous 30 days (+33).

+25 Slightly Bullish 1 article
  • +25 The Single Most Important Metric For Moderna Stock
    • Moderna raised 2026 revenue growth outlook to 15-25% driven by international performance.
    • Cash outflow reached $1.56B due to litigation settlement and working capital swings.

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

125
Show Summary
Show Bulletpoints
Detailed View
Bearish -65

FDA understated risk of heart damage from Moderna COVID vaccine, new study suggests - new.finalcall.com

AI-generated analysis

A study published in the journal Vaccines suggests that Moderna's COVID-19 vaccine (mRNA-1273) presented greater risks than benefits for males aged 18-25, contradicting the FDA's 2022 risk-benefit analysis. The research found that among this demographic, the vaccine was associated with 8% to 52% more hospitalizations for myocarditis and pericarditis than the number of COVID-19 hospitalizations it prevented during a five-month window. Lead author Paul S. Bourdon, Ph.D., and epidemiologist M. Nathaniel Mead argue that the FDA's original model understated risks by assuming uniform hospitalization rates for males aged 18-45 rather than stratifying them correctly. Additionally, the FDA analysis omitted the significant benefits of natural immunity from prior COVID-19 infection, which affected approximately 70% of young men at the time of assessment, thereby skewing the benefit-risk ratio. The new analysis indicates that the FDA's model likely underestimated myocarditis rates and overestimated vaccine effectiveness against hospitalization. Experts cited in the article suggest that the FDA may have worked backward to find an analysis supporting approval despite evidence that risks outweighed benefits for healthy young men, particularly those with prior infections who faced increased heart injury risks. The study calls for more rigorous benefit-risk assessments that account for age, sex, prior infection status, and comorbidities. It highlights international precedents where France suspended Moderna's vaccine use and cites other global studies linking mRNA vaccines to severe myocarditis and pericarditis, noting that the FDA has since required revised labels warning of heart damage risks.

πŸ“‰ Moderna vaccine caused 8%-52% more hospitalizations than prevented for males aged 18-25.

πŸ”¬ FDA assessment criticized for ignoring natural infection protection and uniform age rates.

πŸ“Š Reanalysis shows 0.67 benefit-risk ratio versus FDA's estimated 43:1 favoring vaccination.

⚠️ Experts say FDA model understated risks and overestimated effectiveness unfairly.

🌍 International data confirms high myocarditis risk in South Korea and Japan.

πŸ“‰ A new study in Vaccines found Moderna's COVID-19 vaccine caused 8%-52% more hospitalizations for myocarditis/pericarditis than it prevented for males aged 18-25.

πŸ”¬ The FDA's 2022 benefit-risk assessment is criticized for using uniform hospitalization rates across ages 18-45 and ignoring the protective effects of prior natural infection.

πŸ“Š Reanalysis by lead author Paul Bourdon, Ph.D., shows a benefit-risk ratio of roughly 0.67 compared to the FDA's estimated 43:1 favoring vaccination.

⚠️ Experts claim the FDA model understated myocarditis risks and overestimated vaccine effectiveness, potentially tilting the risk-benefit picture unfairly toward approval.

🌍 International data supports these findings, including a 2024 Nature Communications study showing a 620% higher myocarditis risk in South Korea and high fatality rates in Japan.

πŸ₯ The FDA has since required Pfizer and Moderna to revise vaccine labels with detailed warnings about heart damage risks following similar safety concerns.

πŸ“ Researchers urge the FDA to adopt stratified recommendations based on age, sex, prior infection, and comorbidity status rather than a one-size-fits-all approach.

Bullish Signals
  • Study uses realistic assumptions for transparent reanalysis.
  • 70% of young men had prior natural immunity.
  • Findings align with global studies and 2024 National Academies report.
Risk Factors
  • Higher hospitalization rates for heart inflammation than COVID-19 in young males aged 18-25.
  • FDA analysis may have understated risks and overestimated effectiveness, leading to unsafe recommendations.
  • Increased serious heart injury risk for healthy young men with prior infection after vaccination.
  • Critics allege FDA approval ignored evidence that risks outweighed benefits for healthy young males.
  • Vaccine mandates inappropriate given minuscule COVID-19 danger in this age group.
Bullish Signals
  • The study provides a detailed reanalysis using the FDA's own framework but with more realistic assumptions, offering transparency into how original models may have been flawed.
  • The research highlights that approximately 70% of young men had prior natural immunity, which offers protection equivalent to vaccination but was excluded from the FDA's assessment.
  • The findings align with other global studies and a 2024 National Academies report confirming a causal link between mRNA vaccines and myocarditis, reinforcing independent scientific consensus.
Risk Factors
  • Moderna's vaccine is associated with significantly higher hospitalization rates for heart inflammation (myocarditis/pericarditis) than COVID-19 prevention in young males aged 18-25.
  • The FDA's original risk-benefit analysis may have understated myocarditis risks and overestimated vaccine effectiveness, leading to potentially unsafe recommendations.
  • Healthy young men with prior COVID-19 infection faced increased risks of serious heart injury after vaccination, contradicting claims of safety for this demographic.
  • Critics allege the FDA worked backward to find an analysis supporting approval despite evidence that risks outweighed benefits for healthy young males.
  • The study suggests that vaccine mandates for healthy young people may have been inappropriate given the minuscule danger of COVID-19 itself in this age group.
Somewhat Bullish +45

Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure - Quiver Quantitative

AI-generated analysis

Moderna (MRNA) shares experienced significant volatility following two major catalysts: the departure of the FDA's vaccines chief and a resolved patent dispute. The exit of the FDA official was interpreted by traders as a potential easing of regulatory pressures on mRNA therapies, sparking immediate after-hours gains. Simultaneously, Moderna settled a COVID vaccine patent dispute for $950 million, a figure lower than anticipated, which analysts viewed as a major de-risking event that underscored the company's financial resilience. The stock has rallied 68% year-to-date, driven by optimism regarding pipeline advancements like flu vaccines despite previous regulatory hurdles. While insider trading data reveals four sales totaling over $8.5 million from executives including President Stephen Hoge in the last six months, institutional investors have shown mixed but substantial activity. Notably, FMR LLC and Capital World Investors added hundreds of millions to their portfolios in Q4 2025, while UBS Asset Management significantly reduced its position. Wall Street sentiment remains divided with a split between buy and sell ratings from major firms like Piper Sandler and JP Morgan. Analyst price targets vary widely, ranging from $28 to $69, reflecting uncertainty about the company's future trajectory. Despite the mixed analyst outlook and insider selling, the resolution of legal overhangs and potential regulatory shifts continue to drive bullish sentiment among market participants.

πŸ“ˆ Shares surged after FDA chief departure reduces regulatory pressure.

πŸ’° Company settled patent dispute for $950 million de-risking catalyst.

πŸ“Š Stock gained 68% year-to-date despite prior FDA hurdles.

πŸ‘” Executives sold over $8.5 million in insider trading recently.

βš–οΈ Patent resolution clears path for future approvals and sales.

πŸ“ˆ Moderna shares surged after-hours following reports that the FDA Vaccines Chief will depart in April, interpreted as a reduction in regulatory pressure.

πŸ’° The company settled a COVID vaccine patent dispute for $950 million, a lower-than-expected amount viewed as a significant de-risking catalyst.

πŸ“Š Shares have gained 68% year-to-date as investors focus on pipeline advancements like flu vaccines despite prior FDA hurdles.

πŸ‘” Insider trading data shows four sales totaling over $8.5 million from executives including President Stephen Hoge in the past six months.

🏦 Institutional activity is mixed, with FMR LLC adding $464M and Capital World Investors adding $378M to portfolios in Q4 2025.

πŸ“‰ Conversely, UBS Asset Management removed $184M from its portfolio, while Citadel Advisors reduced holdings by over $41M.

πŸ—£οΈ Analyst ratings are split with Piper Sandler issuing an 'Overweight' rating and target of $69 against multiple 'Underperform' or 'Underweight' ratings from JP Morgan and B of A Securities.

🎯 Price targets for MRNA vary significantly among 12 analysts, ranging from a low of $28 to a high of $69.

βš–οΈ The resolution of the patent litigation removes a major legal overhang, potentially clearing the path for future approvals and commercialization.

Bullish Signals
  • Shares gained after FDA chief departure easing regulatory pressure.
  • $950M lower patent settlement de-risks company significantly.
  • Stock up 68% YTD on pipeline confidence despite hurdles.
  • FMR LLC added $464M to position in Q4 2025.
  • Patent dispute resolution removes legal overhang for growth.
Risk Factors
  • Executives sold over $8.5 million in shares last six months.
  • UBS Asset Management removed $184 million from portfolios in Q4 2025.
  • Analysts are divided with mixed Underperform and Buy ratings.
  • Price targets range widely from $28 to $69.
  • FDA hurdles risk flu vaccine commercialization timelines.
Bullish Signals
  • Moderna shares gained immediately after reports that the FDA Vaccines Chief is leaving, suggesting potential easing of regulatory pressures on mRNA therapies.
  • The $950 million patent settlement was lower than anticipated, providing a major de-risking catalyst and demonstrating strong legal and financial positioning.
  • Shares have appreciated 68% year-to-date, reflecting strong market confidence in the company's pipeline advancements despite previous FDA hurdles.
  • Major institutional investors like FMR LLC added $464 million to their Moderna positions in Q4 2025, indicating significant capital inflow from top-tier funds.
  • The resolution of the patent dispute removes a substantial legal overhang that could have otherwise hindered future product approvals and revenue growth.
Risk Factors
  • Insider trading data reveals four sales totaling over $8.5 million from key executives including President Stephen Hoge in the last six months.
  • Institutional investors like UBS Asset Management significantly reduced their positions, removing $184 million from their portfolios in Q4 2025.
  • Wall Street analyst sentiment is divided, with multiple major firms issuing 'Underperform' or 'Underweight' ratings alongside buy recommendations.
  • Analyst price targets show a wide dispersion ranging from $28 to $69, indicating significant uncertainty regarding the stock's fair value.
  • The company previously faced FDA hurdles for its flu vaccine pipeline, which continues to pose a risk to near-term commercialization timelines.
Bullish +75

Moderna Stock Surges 16% Following Global Patent Litigation Settlement - TIKR.com

AI-generated analysis

Moderna (MRNA) shares surged 16% on March 4 after the company reached a settlement with Arbutus Biopharma and Genevant Sciences regarding patents for its COVID vaccines. The agreement includes a one-time payment of $950 million to Moderna, with no future royalties required. This resolution removes a significant legal overhang that had weighed on investor sentiment for years. Analysts expressed relief at the outcome, noting that the settlement was far better than the feared worst-case scenario which could have involved up to $5 billion in liability. While there remains a potential additional exposure of $1.3 billion if Moderna loses a separate Federal Circuit appeal regarding government contractor immunity, this risk is viewed as manageable compared to the previous uncertainty. The settlement clears the path for future product launches, including mNexspike and mCombriax, and provides Moderna with a concrete cash position expected between $4.5 billion and $5 billion by year-end. Underlying fundamentals are also strengthening, with 2025 revenue reaching $1.9 billion and costs reduced by $2.2 billion year-over-year. Looking ahead, the company is guided for up to 10% revenue growth in 2026 driven by international expansion and continued sales of mNexspike. A major upcoming catalyst is the Phase 3 adjuvant melanoma data from Moderna's cancer vaccine partnership with Merck, which could further validate the company's pipeline potential.

πŸ“ˆ Moderna stock jumped 16% after $950M patent settlement.

πŸ’° Deal clears path for mNexspike with no future royalties.

βš–οΈ Liability avoided worst-case scenario of $5 billion.

πŸ’΅ Company expects $4.5–$5B cash and $2.2B cost cuts.

πŸš€ Revenue guided to grow 10% in 2026 via expansion.

πŸ“ˆ Moderna stock jumped 16% following a $950 million patent settlement with Arbutus Biopharma and Genevant Sciences.

πŸ’° The deal includes no future royalties, providing immediate cash relief and clearing the path for new products like mNexspike.

βš–οΈ Analysts view the outcome as 'better than feared,' avoiding a worst-case liability scenario that could have reached $5 billion.

πŸ›‘οΈ A potential additional $1.3 billion liability exists only if Moderna loses a separate Federal Circuit appeal on government contractor immunity.

πŸ’΅ Moderna expects to finish the year with $4.5–$5 billion in cash, significantly bolstering its balance sheet.

πŸ“‰ Costs were cut by $2.2 billion year-over-year while 2025 revenue reached $1.9 billion.

πŸš€ The company guides for up to 10% revenue growth in 2026 driven by international expansion and mNexspike sales.

🧬 A key upcoming catalyst is Phase 3 adjuvant melanoma data from the partnership with Merck expected later this year.

πŸ“… The settlement covers all worldwide litigation tied to Spikevax and mResvia, removing major legal uncertainty.

Bullish Signals
  • Secured $950M payment strengthening cash without future royalties.
  • Removed legal overhang avoiding feared $5B liabilities.
  • Cut costs by $2.2B while revenue hit $1.9B in 2025.
  • Clears path for mNexspike and mCombriax launches.
  • Provided $4.5–$5B cash runway by year-end.
  • Guides up to 10% revenue growth in 2026.
  • Phase 3 melanoma data from Merck partnership pending.
Risk Factors
  • $1.3B liability risk in 90 days if Moderna loses appeal.
  • Patent disputes continue to cause significant stock volatility.
Bullish Signals
  • Moderna secured a $950 million one-time payment that strengthens its cash position without incurring future royalty obligations.
  • The settlement removes a massive legal overhang, with analysts noting the company 'dodged a bullet' compared to feared $5 billion liabilities.
  • Costs were reduced by $2.2 billion year-over-year while revenue grew to $1.9 billion in 2025, indicating improved operational efficiency.
  • The legal resolution clears the path for future product launches including mNexspike and mCombriax, supporting long-term growth.
  • Management provided a concrete cash runway of $4.5–$5 billion by year-end, giving investors confidence in financial stability.
  • The company is guiding for up to 10% revenue growth in 2026 driven by international expansion and second-year mNexspike sales.
  • A major catalyst remains the Phase 3 adjuvant melanoma data from the Merck partnership, which could validate the cancer vaccine pipeline.
Risk Factors
  • Moderna faces a potential additional liability of $1.3 billion within 90 days if it loses a separate Federal Circuit appeal regarding government contractor immunity.
  • The company still has significant legal history with patent disputes that have caused stock volatility throughout the year.
Slightly Bullish +25

After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

AI-generated analysis

Moderna faces significant financial and regulatory challenges in early 2026 but has secured several strategic wins that could stabilize its future. The company announced it will pay up to $2.25 billion to resolve patent infringement claims with Arbutus Biopharma Corp. and Genevant Sciences GmbH regarding its development of the COVID-19 vaccine, which would be one of the largest patent settlements in history if fully paid. Shortly after this announcement, the FDA reversed a prior decision refusing to review Moderna's flu vaccine for older adults, instead agreeing to evaluate it after addressing initial methodological and safety concerns raised by the agency. To offset these costs and regulatory hurdles, Moderna is aggressively pivoting its strategy toward oncology treatments and rare diseases rather than relying on legacy COVID products or purely infectious disease vaccines that face political scrutiny. The company is collaborating with Merck on cancer vaccines, notably for high-risk melanoma combined with Keytruda, with Phase 3 trial results expected later in the year. Analysts from William Blair and Leerink Partners suggest this diversification could transform Moderna into a revenue-driven oncology company, potentially breaking even despite federal opposition to mRNA technology led by Health and Human Services Secretary Robert F. Kennedy Jr. Despite concerns about cash burn and political hostility toward vaccines from the Trump administration, insiders like co-founder Robert Langer express optimism that the company can navigate this transition. The potential success of its melanoma vaccine and other cancer pipeline targets for lung, kidney, and bladder cancers provides a path toward financial stability. However, experts caution that while infectious disease vaccines may still face political headwinds, the oncology sector represents the critical driver for Moderna's future growth and investor confidence, with cost-sharing arrangements with Merck helping to manage the substantial costs of pivotal studies.

πŸ› Moderna settles $2.25B in patent fees to resolve legacy pandemic legal disputes.

🦠 FDA reversed decision to review mRNA flu vaccine for seniors amid safety concerns.

🧬 Company pivots to oncology, partnering with Merck on cancer therapies and vaccines.

πŸ›οΈ Moderna agreed to pay up to $2.25 billion in settlement fees over patent infringement claims with Arbutus Biopharma and Genevant Sciences.

πŸ’Έ The company will make an initial payment of $950 million, making this one of the largest patent settlements in biotech history.

πŸ›‘ Earlier last month, the FDA initially refused to review Moderna’s flu vaccine application for older adults due to cited safety concerns.

πŸ”„ That regulatory stance has since reversed, with the FDA agreeing to review the mRNA flu vaccine after all.

πŸ“ˆ Despite these setbacks, Moderna’s stock rose over 7% following news of the patent settlement resolution.

🧬 CEO Stéphane Bancel stated that resolving the legacy pandemic matter removes uncertainty and allows focus on future growth.

🎯 Analysts suggest Moderna must diversify away from vaccines into oncology to achieve stability and break even.

πŸ’Š The company is partnering with Merck to develop mRNA cancer therapies for melanoma, lung, kidney, and bladder cancer.

βš–οΈ Federal funding for mRNA vaccine research was cut by HHS Secretary Robert F. Kennedy Jr., but experts view the risk differently for oncology treatments.

🎨 Moderna is shifting its primary revenue driver toward oncology, transforming from a vaccine company to a therapeutics powerhouse.

πŸ”¬ Recent Phase 3 trial results show promising efficacy for an mRNA vaccine combined with Merck’s Keytruda in treating high-risk melanoma.

🀝 A senior FDA official noted that while infectious disease applications haven't pan out yet, oncology benefits are still highly anticipated.

πŸ’° Analysts emphasize that cancer vaccines are the main catalyst for investor optimism regarding Moderna's turnaround potential.

⚠️ However, some experts remain skeptical about whether Moderna will successfully execute this strategic pivot and achieve profitability.

Bullish Signals
  • Moderna stock rose over 7% after settling with Arbutus and Genevant.
  • FDA reversed decision and agreed to review Moderna's mRNA flu vaccine application.
  • Strong Merck partnership creates shared oncology revenue potential for Moderna.
  • Phase 3 trial results show promising cancer vaccine data combined with Keytruda.
  • Leadership is optimistic about transitioning to an oncology-driven business model.
Risk Factors
  • FDA initially refused Moderna mRNA flu vaccine review.
  • HHS Secretary RFK Jr. ends funding for mRNA work.
  • Moderna stops investing in late-stage vaccine trials due to opposition.
  • Moderna burns cash, raising liquidity and sustainability concerns.
  • mRNA platform benefits outside infectious diseases remain unproven.
Bullish Signals
  • Moderna's stock price rallied significantly, rising over 7% following news of the settlement agreement with Arbutus Biopharma Corp. and Genevant Sciences GmbH.
  • The FDA reversed its initial decision to refuse review and agreed to evaluate Moderna's application for its messenger RNA flu vaccine after all.
  • Moderna has secured a strong strategic partnership with Merck, establishing a shared revenue opportunity in oncology that could help the company break even.
  • Promising Phase 3 clinical trial results were recently announced for Moderna's mRNA cancer vaccine combined with Merck's drug Keytruda for treating high-risk melanoma.
  • Management and cofounders, including CEO StΓ©phane Bancel and Robert Langer, expressed optimism about transitioning from a COVID-focused company to one driven by oncology and other indications.
  • Moderna has diversified its pipeline into new areas such as norovirus vaccines and various cancer types including lung, kidney, and bladder cancers, reducing reliance on infectious disease mandates.
  • Investors remain engaged due to the potential for Moderna's 'Hollywood-style redemption arc' driven by its cancer vaccine business and oncology platform benefits.
Risk Factors
  • Moderna faces a potential settlement liability of up to $2.25 billion for patent infringement claims, representing one of the largest such deals in history.
  • The FDA initially refused to review Moderna's application for its messenger RNA flu vaccine for older adults due to methodological and safety concerns regarding trial design.
  • Federal health officials, led by HHS Secretary Robert F. Kennedy Jr., have publicly stated they would no longer fund mRNA vaccine work due to opposition to vaccines.
  • Moderna has announced it will stop investing in late-stage vaccine trials because of growing opposition to vaccines, potentially stalling its infectious disease portfolio.
  • Moderna has a long history of burning cash, raising concerns about its liquidity and ability to sustain operations through current challenges.
  • While some officials note mRNA platform benefits outside infectious diseases have not yet panned out as hoped, this suggests delays or lack of progress in diversifying beyond vaccines.
  • Analysts express uncertainty regarding whether Moderna can successfully execute a turnaround without cancer oncology being the primary revenue driver.
Very Bullish +85

Why Moderna (MRNA) Stock Is Trading Up Today - TradingView

AI-generated analysis

Moderna (MRNA) shares surged 17.4% in the afternoon session after the company settled a long-running patent dispute with Arbutus Biopharma and Genevant Sciences. The agreement, valued at up to $2.25 billion, resolves legal uncertainties surrounding the technology used in its COVID-19 vaccine and eliminates future royalty obligations for Moderna's entire infectious disease portfolio. In addition to the settlement, Moderna received a positive opinion from the European Medicines Agency regarding its combination vaccine for influenza and COVID-19 in individuals aged 50 and older. This regulatory milestone provides clarity for the company's product pipeline and removes significant financial and legal headwinds that had previously weighed on investor sentiment. The stock closed at $57.86, up 16.1% from the previous close, marking a rare but significant move for the volatile biotechnology firm. This rally follows earlier positive news regarding the FDA's acceptance of an amended application for its new seasonal flu vaccine, mRNA-1010, which targets adults aged 50 to 64 and older.

πŸ“ˆ Shares jumped 17.4% after settling patent disputes for up to $2.25 billion.

βš–οΈ Settlement removes future royalties for entire infectious disease portfolio.

πŸ₯ EMA approved combination flu and COVID-19 vaccine for adults 50+.

πŸ’Š FDA accepted amended application for mRNA-1010 flu vaccine targeting ages 50+.

πŸš€ Stock reached new 52-week high of $57.93, up 87.7% this year.

πŸ“ˆ Moderna shares jumped 17.4% after settling a patent dispute with Arbutus Biopharma and Genevant Sciences for up to $2.25 billion.

βš–οΈ The settlement removes future royalty obligations for Moderna's entire infectious disease portfolio, eliminating legal uncertainty.

πŸ₯ EMA issued a positive opinion on Moderna's combination vaccine for flu and COVID-19 in adults aged 50 and older.

πŸ’Š FDA accepted an amended application for the mRNA-1010 seasonal flu vaccine targeting ages 50+ with a target decision of August 5, 2026.

πŸ“‰ Moderna shares are highly volatile, having recorded 50 moves greater than 5% over the last year.

πŸš€ Stock reached a new 52-week high of $57.93 and is up 87.7% since the beginning of the year.

Bullish Signals
  • Removes legal uncertainty impacting stock valuation.
  • Eliminates future royalties on infectious disease portfolio.
  • EMA validates combination vaccine efficacy and safety.
  • FDA accepts amended application for 2026-2027 flu season.
  • Stock hits new 52-week high of $57.93.
Bullish Signals
  • The settlement of the patent dispute removes a major legal and financial uncertainty that had negatively impacted the company's stock valuation.
  • Moderna will not owe future royalties on its infectious disease portfolio, improving long-term profitability prospects.
  • A positive opinion from the European Medicines Agency validates the efficacy and safety of the combination vaccine for influenza and COVID-19 in older adults.
  • The FDA accepted an amended application for the new seasonal flu vaccine, removing a significant regulatory hurdle for the 2026-2027 flu season.
  • Moderna has achieved a new 52-week high of $57.93, reflecting strong investor confidence in its recent developments.